Please ensure Javascript is enabled for purposes of website accessibility

Why Ardelyx Inc. Is Down by Double Digits for a Second Day in a Row

By Brian Orelli, PhD - Updated May 23, 2018 at 1:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The buyers for its secondary stock offering weren't willing to pay up for the biotech.


After the biotech's shares fell almost 20% Tuesday following its announcement that it would be raising capital two different ways, Ardelyx (ARDX 2.14%) stock was trading 14.3% lower early Wednesday afternoon after it revealed the pricing for its secondary stock offering.

So what

Ardelyx will sell 12.5 million shares at $4 per share to raise $50 million in the secondary offering. That's a substantial discount to the $4.55 it closed at Tuesday, and a whopping 29% off the closing price before the company announced it was selling additional shares.

With the buyers of the secondary offering only willing to pay $4 per share, it's no surprise to see shares trading at just under that level Wednesday.

A balance sheet report with a magnifying glass and pen

Image source: Getty Images.

The problem with secondary offerings is that they can dilute shareholders substantially, especially as the price goes down, which pushes up the number of shares that need to be sold in order to raise a set amount of capital.

The underwriters of this offering will also have the option to purchase 1.875 million additional shares. Given that 47.6 million shares were outstanding at the end of the first quarter, this will dilute current shareholders stakes by 23%, assuming the underwriters take that option.

To illustrate what that means, if Ardelyx successfully launches its lead drug candidate, tenapanor, and investors think it's eventually worth a market cap of $476 million, with the current number of shares outstanding, each share would have been worth $10. Now that there will be 61.975 million shares -- again, assuming the underwriters' option is taken -- each share in that scenario would only be worth $7.68. Investors can still making money from here -- and even from where shares were before the secondary offering was announced -- but not as much as they could have made if Ardelyx hadn't needed to raise additional capital.

Now what

There's an old adage in biotech that companies should raise money when they can, not when they need to. Ardelyx doesn't seem to have followed that advice very well, considering that its shares were well over $12 in early 2017. Raising the same amount of capital at $12 per share would have resulted in a dilution of shareholders one-third the magnitude of the one they'll endure now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ardelyx, Inc. Stock Quote
Ardelyx, Inc.
$0.61 (2.14%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.